Human pluripotent stem cells as a platform for precision medicine in diabetes

Published on September 28, 2023   52 min

A selection of talks on Immunology & Inflammation

Please wait while the transcript is being prepared...
0:00
Hi, I'm Essam Abdelalim, senior scientist at Qatar Biomedical Research Institute and associate professor at College of Health and Life Sciences at HBKU University, Qatar Foundation, Qatar. Today I'm going to talk about human pluripotent stem cells as a platform for precision medicine in diabetes.
0:25
Diabetes regardless of the type of diabetes, we know that the problem in case of diabetes is pancreatic beta cells which exist in the endocrine pancreas, those cells secrete insulin. We have different types of diabetes. We know about type one and type two that are the most common types of diabetes. Type one represent around 5% of diabetic patients suffer from type one and mainly happened during early age, mainly in children. In case of type two, which represent the most common form of diabetes. More than 90% of patients suffer from type two, which is mainly genetic. Mainly happened during, after 30 or 40 years old. The cell type, it's monogenic, it's due to defect in the single gene and they represent around or less than 2% worldwide. The fourth one is called gestational diabetes, or temporary, and disappear after pregnancy. To be able to use stem cells for a different type of diabetes, we need to understand what are the types of cells involved within an age problem. In case of type one, patients suffer from or develop has a problem in auto-immune defect, which is his immune cells or her immune cells attack the pancreas to kill beta cells. The patient loose all beta cells or most of beta cells, and this will lead to there is no insulin secretion in response to different concentration of glucose in the blood. The second type is totally different. It has nothing to do with the immune system, it is mainly genetic and the patients suffer from something called the insular resistance in the tissues several years before the development of the disease. This insular resistance happen mainly in skeletal muscle, liver cells, and adipose tissue. Insular resistance there those tissues that mainly use the glucose from the blood or store glucose from the blood, cannot use stored glucose because of insulin. They cannot use insulin which is secreted from the pancreas. Then the pancreas start to see that high level of glucose in the blood and beta cells starts to secrete more and more insulin and become dysfunctional with a time. Insular resistant mainly happened like even 10 or more than 10, 15, 20 years before the development of disease. The cell type it's monogenic, as I mentioned, it's a problem. It's one single gene defect, mutation or defect. Here, what happened it depends on the type of gene or the name of the gene. If the gene transcription factor involved in the development of the pancreatic beta cells. Maybe the patients suffer from developmental defect in the beta which secrete insulin other types of genes may lead to beta cell dysfunction. And maybe also other type everything is okay but impairment in insulin secretion that you have beta cells, everything is normal but insulin is not secreted from the beta cells and also in some cases we see patients they don't have even pancreas was called pancreatic hypoplasia or agenesis due to defect in one gene. All of different types of diabetes can lead to complications as all of us know. How we can use stem cells or cell therapy for 2, 3 diabetes? This is what we'll know.
Hide

Human pluripotent stem cells as a platform for precision medicine in diabetes

Embed in course/own notes